Trade secrets: an alternative for life sciences IP?

Over the past decade, three high-profile US Supreme Court decisions—known by their shorthand names as Alice, Mayo, and Myriad—have generated significant uncertainty over what is and isn’t patentable.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

Careers

Wilson Sonsini senior counsel moves to a rival firm

6 February 2026 The New York-based partner will advise biotech, pharma, and technology clients on patent prosecution, IP strategy and venture-backed transactions.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

Nine-partner litigation team leaves Winston & Strawn

LSPN Awards USA returns for second year—with new categories

Firm adds seven-lawyer team in second major merger

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Senior four-partner team leaves A&O Shearman

Why the US is poised for a patent litigation surge in 2026

From migraine drugs to COVID vaccine spats, US lawsuits pile up

How AI will be shaped by legal and regulatory developments in 2026

Trade secrets: an alternative for life sciences IP?

More on this story

Editor's picks

Editor's picks

More features